Hemorrhagic Shock Treatment Market, by Drug, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

PUBLISHED: May 31, 2022

PAGES: 155 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Hemorrhagic shock is a condition that results in reduced tissue perfusion and inadequate delivery of oxygen and nutrients to cells. A traumatic injury may lead to hemorrhagic shock if bleeding is not stopped immediately. The primary treatment for hemorrhagic shock is to immediately control the source of bleeding and to replace the fluid. In CHS (Controlled Hemorrhagic Shock), the fluid replacement is to normalise hemodynamic parameters where the source of bleeding has been stopped.

Global Hemorrhagic Shock Treatment Market Dynamics

Factors such as the increasing consumption of anti-hypertensive drugs and burden of chronic diseases across the globe are expected to propel the market growth. For instance, according to statistics provided by the World Health Organization, the chronic disease burden was 47% in 2001 and is predicted to increase to 57% by 2020.

Moreover, a rise in the number of ischemic strokes, coupled with the increasing consumption of tobacco is also expected to drive the market growth. According to the World Stroke Organization (WSO), there were over 9.5 million novel cases of ischemic stroke in 2016, of which 52% were men.

Key features of the study:

This report provides in-depth analysis of the global hemorrhagic shock treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hemorrhagic shock treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study are F. Hoffmann-La Roche Ltd, Biomedica Management Corporation, Leading BioSciences, Inc., NuvOx Pharma LLC, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc, Boehringer Ingelheim International GmbH, AstraZeneca, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company, Limited, Novartis AG, Amneal Pharmaceuticals LLC, and Zydus Cadila.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hemorrhagic shock treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the global hemorrhagic shock treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Hemorrhagic Shock Treatment Market, By Drug:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
Global Hemorrhagic Shock Treatment Market, By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Channels
Global Hemorrhagic Shock Treatment Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
  - By Drug:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
  - By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Channels
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
  - By Drug:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
  - By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Channels
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
  - By Drug:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
  - By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Channels
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
  - By Drug:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
  - By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Channels
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
  - By Drug:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
  - By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Channels
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
  - By Drug:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
  - By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Channels
Company Profiles
- F. Hoffmann-La Roche Ltd
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Biomedica Management Corporation
- Leading BioSciences, Inc.
- NuvOx Pharma LLC
- Bristol-Myers Squibb Company
- Johnson & Johnson Services Inc.
- Boehringer Ingelheim International GmbH
- AstraZeneca
- Teva Pharmaceutical Industries Ltd.
- Daiichi Sankyo Company, Limited
- Novartis AG
- Amneal Pharmaceuticals LLC
- Zydus Cadila

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI4097

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Technological Advancements in Hemorrhagic Shock Treatment
Key Developments
Acquisition, Collaborations & Partnerships
Epidemiology
Pipeline Analysis
PEST Analysis

4. Global Hemorrhagic Shock Treatment Market, Impact of Coronavirus (COVID-19) Pandemic

Pre-COVID situation
Post-COVID demand
Need for Hemorrhagic Shock Treatment
Recommendations and guidelines by regulatory bodies

5. Global Hemorrhagic Shock Treatment Market, By Drug, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
NVX-408
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
YW-356
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
LB-1148
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Neutrolide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Hemorrhagic Shock Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Channels
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Hemorrhagic Shock Treatment Market, By Region, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
Europe
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Africa
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
Middle East
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC
- Israel
- Rest of Middle East

8. Competitive Landscape

Company Profiles
- Biomedica Management Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- NuvOxPharma LLC
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Leading BioSciences, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Johnson & Johnson Services Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AstraZeneca
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Daiichi Sankyo Company, Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ZydusCadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Amneal Pharmaceuticals LLC
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies